Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma

Significant advances in the treatment of melanoma have been made with BRAF-targeted therapy and immune checkpoint blockade, and these strategies are now being combined empirically in clinical trials. Potential synergy is demonstrated in murine models and in analysis of longitudinal biopsies from pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooper, Zachary A, Reuben, Alexandre, Amaria, Rodabe N, Wargo, Jennifer A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292518/
https://www.ncbi.nlm.nih.gov/pubmed/25941608
http://dx.doi.org/10.4161/21624011.2014.954956
Descripción
Sumario:Significant advances in the treatment of melanoma have been made with BRAF-targeted therapy and immune checkpoint blockade, and these strategies are now being combined empirically in clinical trials. Potential synergy is demonstrated in murine models and in analysis of longitudinal biopsies from patients on trial, however important questions remain regarding toxicity, optimal timing and sequence of therapy.

Ejemplares similares